Top

Published in:

01-06-2006 | Original Article

CXCL12-3′A Polymorphism and lung cancer metastases protection: new perspectives in immunotherapy?

Authors: Ana Coelho, Carmen Calçada, Raquel Catarino, Daniela Pinto, Graça Fonseca, Rui Medeiros

Published in: Cancer Immunology, Immunotherapy | Issue 6/2006

Excerpt

Lung cancer remains a major worldwide health problem, being the most common form of cancer in the world, both in terms of incidence, 12.3% of all cancers (with an estimated 1.2 million new cases in 2000), and mortality (1.1 million deaths in 2000), representing 17.8% of the total number of deaths caused by cancer. More than half of the new cases occur in more developed countries (52%), with incidence rates lower in women (11.1 per 1,000,000), than in men (34.9 per 1,000,000) [17]. …

Balkwill F (2004) Cancer and the chemokine network. Nat Rev Cancer 4:540–550PubMedCrossRef

Benovic JL, Marchese A (2004) A new key in breast cancer metastases. Cancer Cell 6:429–430PubMedCrossRef

Epstein RJ (2004) The CXCL12-CXCR4 chemotactic pathway as a target of adjuvant breast cancer therapies. Nat Rev Cancer 4:1–9CrossRef

Hart I, Fidler I (1980) Role of organ selectivity in the determination of metastatic patterns of B16 melanoma. Cancer Res 40:2281–2287PubMed

Hoffman PC, Mauer AM, Vokes EE (2000) Lung cancer. Lancet 355:479–485PubMed

Homey B, Muller A, Zlotnik A (2002) Chemokines: agents for the immunotherapy of cancer? Nat Rev Immunol 2:175–184PubMedCrossRef

Kaplan E, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481CrossRef

Kristiansen B, Knudsen TB, Ohlendorff S, Eugen-Olsen J (2001) A new multiplex PCR strategy for the simultaneous determination of four genetic polymorphisms affecting HIV-1 disease progression. J Immunol Methods 252:147–151PubMedCrossRef

Kucia M, Jankowski K, Reca R, Wysoczynski M, Bandura L, Allendorf DJ, Zhang J, Ratajczak J, Ratajczak MZ (2004) CXCR4–SDF-1 signalling, locomotion, chemotaxis and adhesion. J Mol Histol 35:233–245PubMedCrossRef

10.

Liotta LA (2001) An attractive force in metastasis. Nature 410:24–25PubMedCrossRef

11.

Miller S, Dykes D, Polesky H (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215PubMedCrossRef

12.

Minna JD, Roth JA, Gazdar AF (2002) Focus on lung cancer. Cancer Cell 1:49–52PubMedCrossRef

13.

Mochizuki H, Matsubara A, Teishima J, Mutaguchi K, Yasumoto H, Dahiya R, Usui T, Kamiya K (2004) Interaction of ligand–receptor system between stromal-cell derived factor-1 and CXC chemokine receptor 4 in human prostate cancer: a possible predictor of metastasis. Biochem Biophys Res Commun 320:656–663PubMedCrossRef

14.

Müller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verástegul E, Zlotnik A (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410:50–56PubMedCrossRef

15.

Murakami T, Cardones AR, Hwang ST (2004) Chemokine receptors and melanoma metastasis. J Dermatol Sci 36:71–78PubMedCrossRef

16.

Parkin DM (2001) Global cancer statistics in the year 2000. Lancet Oncol 2:533–543PubMedCrossRef

17.

Phillips RJ, Burdick MD, Lutz M, Belperio JA, Keane MP, Strieter RM (2003) The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am J Respir Crit Care Med 167:1676–1686PubMedCrossRef

18.

Proudfoot AEI (2002) Chemokine receptors: multifaceted therapeutic targets. Nat Rev Immunol 2:106–115PubMedCrossRef

19.

Rosell R, Felip E, Garcia-Campelo R, Balaña C (2004) The biology of non-small-cell lung cancer: identifying new targets for rational therapy. Lung Cancer 46:135–148PubMedCrossRef

20.

Samara G, Lawrence D, Chiarelli CJ, Valentino MD, Lyubsky S, Zucker S, Vaday GG (2004) CXCR4-mediated adhesion and MMP-9 secretion in head and neck squamous cell carcinoma. Cancer Lett 214:231–241PubMedCrossRef

21.

Schrader A, Lechner O, Templin M, Dittmar K, Machtens S, Mengel M, Probst-Kepper M, Franzke A, Wollensak T, Gatzlaff P, Atzpodien J, Buer J, Lauber J (2002) CXCR4/CXCL12 expression and signalling in kidney cancer. Br J Cancer 86:1250–1256PubMedCrossRef

22.

Soriano Á, Martínez C, García F, Plana M, Palou E, Lejeune M, Aróstegui JI, Lazzari ED, Rodriguez C, Barrasa A, Lorenzo JI, Alcamí J, Romero Jd, Miró JM, Gatell JM, Gallart T (2002) Plasma stromal cell-derived factor (SDF)-1 levels, SDF1-3’A genotype, and expression of CXCR4 on T lymphocytes: their impact on resistance to human immunodeficiency virus type 1 infection and its progression. J Infect Dis 186:922–931PubMedCrossRef

23.

Strieter RM, belperio JA, Burdick MD, Sharma S, Dubinett SM, Keane MP (2004) CXC chemokines angiogenesis, immunoangiostasis, and metastases in lung cancer. Ann NY Acad Sci 1028:1–10CrossRef

24.

Winkler C, Modi W, Smith MW, Nelson GW, Wu X, Carrington M, Dean M, Honjo T, Tashiro K, Yabe D, Buchbinder S, Vittinghoff E, Goedert JJ, O’Brien TR, Jacobson LP, Detels R, Donfield S, Willoughby A, Gomperts E, Vlahov D, Phair J, O’Brien SJ (1998) Genetic restriction of AIDS pathogenesis by an SDF-1 Chemokine Gene Variant. Sci 279:389–393CrossRef

25.

Zafiropoulos A, Crikas N, Passam AM, spandidos DA (2004) Significant involvement of CCR2-64I and CXCL12-3’A in the development of sporadic breast cancer. J Med Genet 41:e59PubMedCrossRef

26.

Zlotnik A (2004) Chemokines in neoplastic progression. Semin Cancer Biol 14:181–185PubMedCrossRef

Title: CXCL12-3′A Polymorphism and lung cancer metastases protection: new perspectives in immunotherapy?
Authors: Ana Coelho
Carmen Calçada
Raquel Catarino
Daniela Pinto
Graça Fonseca
Rui Medeiros
Publication date: 01-06-2006
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 6/2006
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-005-0062-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 6/2006

Morphological appearance, content of extracellular matrix and vascular density of lung metastases predicts permissiveness to infiltration by adoptively transferred natural killer and T cells

Flow Cytometric analysis of Th1 and Th2 cytokines in PBMCs as a parameter of immunological dysfunction in patients of Superficial Transitional cell carcinoma of bladder

Expression of CD45 and proliferative response to CD3 as suitable classification markers of patients with gastric adenocarcinoma

ESTDAB: a collection of immunologically characterised melanoma cell lines and searchable databank

Monoclonal antibody A7 coupled to magnetic particles as a contrast enhancing agent for magnetic resonance imaging of human colorectal carcinoma

A new LAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-A68 tumors

Keynote webinar | Spotlight on antibody–drug conjugates in cancer